Short Interest in Cel-Sci Corporation (NYSEAMERICAN:CVM) Increases By 67.2%

Cel-Sci Corporation (NYSEAMERICAN:CVM) was the recipient of a large increase in short interest in July. As of July 31st, there was short interest totaling 1,200,354 shares, an increase of 67.2% from the July 15th total of 718,008 shares. Based on an average daily trading volume, of 316,846 shares, the short-interest ratio is currently 3.8 days. Approximately 8.0% of the company’s stock are sold short.

Institutional Trading of Cel-Sci

A number of hedge funds have recently made changes to their positions in the stock. US Bancorp DE purchased a new stake in shares of Cel-Sci in the 3rd quarter worth approximately $80,000. HighTower Advisors LLC purchased a new position in Cel-Sci during the fourth quarter valued at $53,000. HRT Financial LP bought a new stake in Cel-Sci in the fourth quarter worth $60,000. XTX Topco Ltd bought a new stake in Cel-Sci in the fourth quarter worth $66,000. Finally, Renaissance Technologies LLC purchased a new stake in shares of Cel-Sci in the fourth quarter worth $81,000. 12.08% of the stock is owned by institutional investors.

Cel-Sci Stock Up 2.6%

Shares of Cel-Sci stock traded up $0.04 during trading on Tuesday, hitting $1.59. The company’s stock had a trading volume of 228,458 shares, compared to its average volume of 269,545. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.54 and a current ratio of 0.60. The company has a fifty day simple moving average of $1.23 and a two-hundred day simple moving average of $2.65. The company has a market capitalization of $27.79 million, a PE ratio of -0.16 and a beta of 0.63. Cel-Sci has a 52 week low of $0.89 and a 52 week high of $13.48.

Cel-Sci (NYSEAMERICAN:CVM) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.47) EPS for the quarter.

Cel-Sci Company Profile

CEL-SCI Corporation is a biotechnology company focused on the development of immunotherapy products to treat cancer and infectious diseases. Founded in 1983 and headquartered in Vienna, Virginia, the company applies its proprietary LEAPS® (Ligand Epitope Antigen Presentation System) and Multikine® immunotherapy platforms to stimulate the body’s immune response against disease. CEL-SCI operates as a clinical-stage enterprise, working to translate immunological insights into therapeutic candidates.

The company’s lead product candidate, Multikine (leukineferon), is an investigational immunotherapy designed to enhance the immune system’s ability to attack head and neck cancer cells.